(Q46170735)

English

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

scientific article published on 5 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Todd D Tillmanns

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

M Patrick Lowe

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Mark S Walker

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Edward J Stepanski

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Lee S Schwartzberg

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

language of work or name

0 references

publication date

5 September 2012

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Gynecologic Oncology

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

128

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

221-228

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Overview of anti-angiogenic agents in development for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.08.039

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.08.039

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

release_qubxmoa4vjgbrkepfpxmfd5xia

1 reference

https://api.fatcat.wiki/v0/release/qubxmoa4vjgbrkepfpxmfd5xia

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/22960352

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46170735&oldid=2096517573"